Maxim Group Upgrades Theriva Biologics to Buy, Announces $1 Price Target
Benzinga Newsdesk 7 months ago
NewsUpgradesPrice TargetAnalyst Ratings
Maxim Group analyst Jason McCarthy upgrades Theriva Biologics (AMEX:TOVX) from Hold to Buy and announces $1 price target.
Maxim Group analyst Jason McCarthy upgrades Theriva Biologics (AMEX:TOVX) from Hold to Buy and announces $1 price target.